FDA Approves First Drug to Treat SMA Muscle Loss, While CDC Clears Lettuce Outbreak

The FDA just approved Isembyld, the first-ever therapy targeting muscle loss in spinal muscular atrophy (SMA), a rare neurological disorder that devastates movement. In late-stage trials, young patients combining Isembyld with existing SMN2-targeting drugs saw their motor skills improve after a year, while placebo groups declined—a significant win for the SMA community.

From Lab to Lunch Plate

Meanwhile, the CDC declared the **largest cyclospora...